D
Danny Cassimon
Researcher at University of Antwerp
Publications - 99
Citations - 1909
Danny Cassimon is an academic researcher from University of Antwerp. The author has contributed to research in topics: Debt & Internal debt. The author has an hindex of 20, co-authored 93 publications receiving 1551 citations. Previous affiliations of Danny Cassimon include International Monetary Fund.
Papers
More filters
Journal ArticleDOI
Inequality, ICT and financial access in Africa
TL;DR: In this article, the authors investigated the role of information and communication technology (ICT) on income inequality through financial development dynamics of depth (money supply and liquid liabilities), efficiency (at banking and financial system levels), activity (from banking and finance system perspectives) and size, in 48 African countries for the period 1996 to 2014.
Journal ArticleDOI
Evidence on Changes in Aid Allocation Criteria
TL;DR: This paper found that after the fall of the Berlin wall in 1989 and especially in the late 1990s, bilateral aid responded more to poverty and the quality of the policy and institutional environment in the recipient countries, and the sensitivity of aid allocation to the country's size and its debt burden has declined over time.
Posted Content
Investment, uncertainty and irreversibility: evidence from belgian accounting data
TL;DR: In this paper, the authors investigated the effects of uncertainty on the investment behavior using firm-level data for a sample of Belgian manufacturing firms and found that uncertainty has mainly an impact on the decision to invest and to a much lesser extent on the amount invested.
Journal ArticleDOI
The valuation of a NDA using a 6-fold compound option
TL;DR: This paper derives a closed-form solution for a n -fold compound option model, and applies it to calculate the value of a NDA using sector average figures.
Posted Content
Incorporating Technical Risk in Compound Real Option Models to Value a Pharmaceutical R&D Licensing Opportunity
Danny Cassimon,Marianne D. De Backer,Peter-Jan Engelen,Peter-Jan Engelen,Martine van Wouwe,Vilimir Yordanov +5 more
TL;DR: This model is extended by explicitly incorporating technical risk, while still preserving the closed-form solution of the model, and is better suited to handle real-life valuation cases in the pharmaceutical industry.